Clinical trial · no report yet · Phase 2
NCT06248515
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
- NCT06248515 ↗
- Recruiting
- Georgetown University
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Parallel Arm Study of SACITUZUMAB GOVITECAN-HZIY in Patients With Advanced Thymoma and Thymic Carcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Thymoma; Thymic Carcinoma
- Interventions
- Sacituzumab govitecan-hziy
- Arms
- Sacituzumab · Experimental
- Enrollment
- 18 (estimated)
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Georgetown University with Gilead Sciences
- Start
- Apr 25, 2024
- Primary completion
- May 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06248515 · updated Sep 11, 2026